new medical use, pharmaceutical compositions and method of reversion of the resistance the quimioterapics

NOVELTY – The phosphatase protein inhibitors based elimination of cancer cells chemotherapy resistance comprises restoration of the sensitivity of the cancer cells to the therapy. Also claimed is a pharmaceutical implementing the process. CLAIMED PHARMACEUTICAL – The pharmaceutical contains antineoplastic agents, and is also effective in the treatment of diseases caused by bacteria and e.g fungi. USE – In physical chemistry.

Main Application Field

B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); D16 (Fermentation industry – including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)

INVENTORS:

FERREIRA CARMEN VERISSIMA
AOYAMA HIROSHI
QUEIROZ KARLA CRISTINA DE SOUZ
PEPPELENBOSCH MAIKEL PETRUS
SILVA MARIA AUGUSTA SARTORI DA
JUCA MARILENA BEZERRA

142_FOSFATASES

Patent number: BR200604691-A

PATENT STATUS:

For information contact Inova Unicamp

FOR ADDITIONAL INFORMATION:

parcerias@inova.unicamp.br

+55 (19) 3521-5207 / 2607